Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Forsta AP Fonden

Forsta AP Fonden boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 26,400 shares of the biopharmaceutical company’s stock after buying an additional 600 shares during the quarter. Forsta AP Fonden’s holdings in Alnylam Pharmaceuticals were worth $8,609,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $30,000. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth approximately $27,000. Ameritas Advisory Services LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $42,000. AlphaQuest LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $43,000. Finally, Parkside Financial Bank & Trust increased its position in Alnylam Pharmaceuticals by 32.6% during the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 44 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 0.3%

NASDAQ:ALNY opened at $453.97 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The firm has a market capitalization of $59.98 billion, a PE ratio of -183.79 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The business’s 50-day moving average is $458.86 and its two-hundred day moving average is $381.74.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ALNY shares. BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Evercore ISI upped their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Finally, Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Twenty-three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $482.17.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares in the company, valued at $29,568,138.45. This trade represents a 12.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the transaction, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 66,696 shares of company stock valued at $30,430,694. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.